Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 20/20 | 1.00 |
| ▸ | ITGA4 | P13612 | 20/20 | 1.00 |
| ▸ | ITGB7 | P26010 | 20/20 | 1.00 |
| ▸ | ITGAV | P06756 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2846116 | 0.93 | ITGB1 (1.00) | ITGB1ITGA4ITGB7 | |
| SCHEMBL2846062 | 0.92 | ITGB1 (0.85) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL2846063 | 0.92 | ITGB1 (0.85) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL2951232 | 0.90 | ITGB1 (0.88) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL2956354 | 0.90 | ITGB1 (1.00) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL13671399 | 0.90 | ITGB1 (1.00) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL2846093 | 0.89 | ITGB1 (0.86) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL2953329 | 0.89 | ITGB1 (0.97) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL1413124 | 0.89 | ITGB1 (0.86) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL1413051 | 0.89 | ITGB1 (0.85) | ITGB1ITGA4ITGB7ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820687-B2 | Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | claimed |
| EP-2231185-A1 | METHODS AND COMPOSITIONS FOR TREATING LIQUID TUMORS | Elan Pharmaceuticals Inc. (US) | 2010-09-29 | — | — | EP | claimed |
| US-20100016345-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | claimed |
| US-20090312353-A1 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. | 2009-12-17 | — | — | US | claimed |
| US-7579466-B2 | Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | claimed |
| WO-2009075806-A1 | METHODS AND COMPOSITIONS FOR TREATING LIQUID TUMORS | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | claimed |
| EP-1996559-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals Inc. (US) | 2008-12-03 | — | — | EP | claimed |
| US-20080058357-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2008-03-06 | — | — | US | claimed |
| WO-2007101165-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-09-07 | — | — | WO | claimed |
| US-8269009-B2 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8269009-B2 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8269009-B2 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-7820687-B2 | Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820687-B2 | Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| WO-2009075806-A1 | METHODS AND COMPOSITIONS FOR TREATING LIQUID TUMORS | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| EP-1996559-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20080058357-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058357-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058357-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2007101165-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016345-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | VCAM1, ICAM1, CD4 | ITGB1 110/4885ITGA4 10/4885ITGB7 747/4885 |
| US-20090312353-A1 | Methods and compositions for treating liquid tumors | ITGB4, ITGA4, ITGB3 | ITGB1 4/4885ITGA4 2/4885ITGB7 13/4885 |
| US-20080058357-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | VCAM1, ICAM1, CD4 | ITGB1 110/4885ITGA4 10/4885ITGB7 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.